Project chronology & history

Tafalgie Therapeutics is a company created in October 2020.

It brings together researchers and entrepreneurs, whose objective is to valorize more than 10 years of fundamental research conducted by Dr. Aziz Moqrich and his team.

This work has been the subject of numerous publications and the filing of an international patent (by the SATT on behalf of the CNRS and AMU) about a new protein used as a potential analgesic against inflammatory and neuropathic pain.

The key stages of the project were numerous, from research to development :

The others key stages

2005-2006

Creation of the team 'Chronic Pain'

Creation of the team 'Chronic Pain' :

Molecular and cellular mechanism by Dr. Aziz Moqrich at the IBDL & Dr. Stephane Gaillard who joined the team

2020

Sub-licence exploitation agreement

Sub-licence exploitation agreement

with Satt Sud-Est

Who is SATT SUD-EST ?

2019-2020

Creation of Tafalgie Therapeutics & company

Creation of the company

Tafalgie Therapeutics finalizing the founders' round table with the arrival of Laurent Labatut and the establishment of a support team

2022

The company enters into operation

Company enters into operation

with pre-clinical studies, R&D activités, regulatory activities, Scientific Advisory Board, and search for financial support

Contact-us
for more information

JOIN-US

Follow-us to know the actuality

Tafalgie Therapeutics

Spin off from CNRS and AMU is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous and secreted protein modulating the pain signal.

Pages

Réalisé avec ❤️